Effects of Sorafenib and Radiofrequency Ablation on Hepatacellular carcinoma.
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Pharmacogenomic; Therapeutic Use
- 21 May 2012 Planned end date changed from 1 Dec 2010 to 31 Dec 2012 as reported by Chinese Clinical Trial Register.
- 19 Nov 2010 New trial record